RxSight, Inc. Common Stock (RXST) is a publicly traded Healthcare sector company. As of May 21, 2026, RXST trades at $6.02 with a market cap of $248.38M and a P/E ratio of -5.38. RXST moved +3.53% today. Year to date, RXST is -41.11%; over the trailing twelve months it is -62.94%. Its 52-week range spans $5.30 to $55.57. Analyst consensus is neutral with an average price target of $9.83. Rallies surfaces RXST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RxSight Q1 Sales Fall 18.5% to $30.9M While Installed Base Tops 1,154: RxSight reported $30.9 million in Q1 sales, down 18.5%, driven by 27,472 Light Adjustable Lens units and 20 Light Delivery Devices expanding the installed base to 1,154. Gross margin rose to 76.1%, expenses rose to $41.3 million, net loss widened to $15.9 million, and New Zealand approval broadens global footprint.
| Metric | Value |
|---|---|
| Price | $6.02 |
| Market Cap | $248.38M |
| P/E Ratio | -5.38 |
| EPS | $-1.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $55.57 |
| 52-Week Low | $5.30 |
| Volume | 103 |
| Avg Volume | 0 |
| Revenue (TTM) | $127.48M |
| Net Income | $-46.64M |
| Gross Margin | 77.02% |
9 analysts cover RXST: 0 strong buy, 1 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $9.83.